Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The project has priority review, but deaths could raise eyebrows.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Arcellx and AstraZeneca take centre stage.
